Official websites use. Share sensitive information only on official, secure websites. Correspondence: Q. For commercial re-use, please contact journals. Acute HIV-2 infection is rarely observed, only 2 primary infections have been described to date. We report a detailed case of HIV-2 primary infection in a year-old French bisexual Caucasian man, thereby providing valuable insights into HIV-2 early infection.
Three weeks before V1, he exhibited a generalized maculopapular rash that lasted for 3 days. He reported no history of diarrhea or weight loss. Clinical examination revealed no signs of pharyngitis, fever, adenopathy, or organomegaly. Chest radiography yielded normal chest findings. He reported having engaged in unprotected anal and oral sexual encounters with 15 male individuals between March of and April of Three of these individuals had been unknown to him, and none of them came from HIVendemic areas in West Africa.
His last at-risk exposure occurred 5 weeks before, in mid-March , with an unknown individual, with whom he engaged in unprotected receptive anal intercourse that involved ejaculation and unprotected mutual oral sex. The patient had a negative HIV serology 1 year before presentation.
Screening for other sexually transmitted infections syphilis, hepatitis B virus, hepatitis C virus, Neisseria gonorrhoeae, and Chlamydia trachomatis was negative. The signal was weakly positive 2. Combined antiretroviral therapy was hence initiated 1 week after V2, with a regimen containing emtricitabine, tenofovir disoproxil fumarate, and ritonavir-boosted darunavir.
Due to HIV-2 natural drug resistance to non-nucleoside reverse transcriptase inhibitors, the recommended firstline treatment options consist of 2 nucleoside reverse transcriptase inhibitors associated with a protease or integrase inhibitor.
